Home/Theripion/Jeffery Ledbetter, Ph.D.
JL

Jeffery Ledbetter, Ph.D.

CEO

Theripion

Theripion Pipeline

DrugIndicationPhase
TR-43Ischemia-Reperfusion Injury, Cardiovascular Disease, Inflammatory Bowel Disease, Cystic Fibrosis, Rheumatoid Arthritis, Neurodegenerative DiseasesPre-clinical
Ther4Alzheimer’s Disease, Cardiovascular DiseasePre-clinical
TR-45Rheumatoid ArthritisPre-clinical